Results 1 to 10 of about 12,537 (178)

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Therapeutics and Clinical Risk Management, 2023
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Suzanne Lentzsch
exaly   +3 more sources

Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss [PDF]

Antibodies
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding ...
Marco Allinovi, Luca Malatesta, Tiziana Biagioli, Elisabetta Antonioli, Federico Perfetto   +4 more
doaj   +3 more sources

Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials [PDF]

Frontiers in Immunology
Although daratumumab has been reported to significantly improve the prognosis of multiple myeloma (MM), its efficacy in patients with cytogenetically high-risk MM (HRMM) remains unclear.
Liang Su, Minlan Ye, Bowen Peng, Lei Fan, Jie Wu   +4 more
doaj   +2 more sources

Daratumumab in untreated newly diagnosed multiple myeloma

Therapeutic Advances in Hematology, 2019
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Shaji Kumar, Nadine Abdallah
exaly   +2 more sources

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Journal of Translational Autoimmunity, 2019
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Sonja Zweegman, Henny Otten
exaly   +3 more sources

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in Oncology, 2021
Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different
Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione   +6 more
doaj   +1 more source

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

Frontiers in Oncology, 2022
BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion
Francesca Bonello, Serena Rocchi, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Marco Talarico, Elena Zamagni, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Michele Cavo, Roberto Mina   +18 more
doaj   +1 more source

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

HemaSphere, 2023
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but
Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Carolien Duetz, Chloe A. O’Neill, Wassilis S.C. Bruins, Paola M. Homan-Weert, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Tineke Casneuf, Yann Abraham, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Elena Ramos, Raluca I. Verona, Maria Krevvata, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. van de Donk   +26 more
doaj   +1 more source

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

Frontiers in Oncology, 2023
Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration ...
Gordon Cook, John Ashcroft, John Ashcroft, Mariana Fernandez, Sarah Henshaw, Zeyad Khalaf, Guy Pratt, Anish Tailor, Neil Rabin   +8 more
doaj   +1 more source

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Haematologica, 2020
Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari   +16 more
doaj   +1 more source